Tech & Gadgets

Is this 'de-extinction' project actually onto something?

20 sec read15 views0 listens

Dallas-based startup Colossal has secured significant funding for its "de-extinction" projects, aiming to recreate lost animals like the woolly mammoth and Tasmanian tiger. This ambitious endeavor highlights the intersection of genetics and biotech, offering developers and tech professionals a前沿技术的试验场，可能引领未来生物多样性保护的新方法。接下来需关注的是这些项目如何应对科学准确性与公众期望之间的挑战。

Read the full article at The Verge

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO

Parabilis Medicines achieved a record-breaking $770.5 million IPO, the largest ever for a drug developer, with its stock experiencing a significant initial jump. This event is highly relevant for developers and professionals in the biotech and pharma...

Ali Nemati

Health & MedicineApr 3026 sec read

STAT+: Hair-raising trial results, and Servier's M&A wishlist

Veradermics CEO Reid Waldman discussed the company's promising data on hair loss treatments, while Servier Pharmaceuticals CEO David Lee outlined plans post-acquisition of Day One Biopharmaceuticals. These developments highlight growing investor inte...

Ali Nemati

Health & MedicineMar 3127 sec read

STAT+: Biotech VCs move upstream in China's scientific pipelines as competition grows fiercer

U.S. venture capital firms are increasingly embedding themselves in Chinese labs and courting scientists before their research is published, moving upstream in biotech investments due to fierce competition and rising valuations. This shift impacts te...

Ali Nemati

Health & MedicineMar 1128 sec read

STAT+: A top biotech VC quietly helped Epstein's 'great friend' make a comeback

Despite Boris Nikolic's tarnished reputation due to his association with Jeffrey Epstein, venture capitalist Alexis Borisy helped him raise over $100 million for a new fund through Curie.Bio, facilitating Nikolic’s comeback in the biotech industry. T...

Ali Nemati

Health & MedicineMar 520 sec read

STAT+: Cognito raises $105 million for Alzheimer's treatment device

Cognito Therapeutics raised $105 million for its Alzheimer's treatment device, Spectris, awaiting FDA clearance post-clinical trial results; this significant funding underscores growing investor interest in innovative neurodegenerative disease treatm...

Ali Nemati

Is this 'de-extinction' project actually onto something?

Related Articles

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO

STAT+: Hair-raising trial results, and Servier's M&A wishlist

STAT+: Biotech VCs move upstream in China's scientific pipelines as competition grows fiercer

STAT+: A top biotech VC quietly helped Epstein's 'great friend' make a comeback

STAT+: Cognito raises $105 million for Alzheimer's treatment device